Concizumab for people with hemophilia and inhibitors
Treatments studied
Part of Blood & lymphatic clinical trials.
This program gives access to concizumab, a medicine that helps prevent bleeding, for people with hemophilia who have inhibitors or can't use standard treatments. It's for when other options have not worked well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have inherited hemophilia A or B.
- You either have severe hemophilia A (factor VIII less than 1%) or moderate/severe hemophilia B (factor IX 2% or lower), without inhibitors.
- Or you have any severity of hemophilia with a documented history of inhibitors (a level of 0.6 or higher) and cannot use approved treatments because of inhibitors, allergic reactions, or poor vein access.
- You cannot join clinical trials testing concizumab for other reasons (such as inhibitors, allergies, or vein problems).
- The likely benefits of this treatment must outweigh its risks for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial will track how well Alhemo works and how safe it is for people with hemophilia A or B in everyday use. If you are 12 or older and your doctor has already decided to start you on Alhemo, this study will collect information to help doctors better understand the medicine's real-world benefits and risks.
This study is tracking how well Alhemo works in people with hemophilia A or B who have developed inhibitors (antibodies that block treatment). It is for patients of any age who have already started taking Alhemo as part of their regular care.
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
This trial studies Hemlibra (emicizumab) in people with mild congenital hemophilia A to see how well it works and what safety issues may occur. It may help reduce bleeding in patients who meet the study’s specific health and safety requirements.
This study collects real-world information on how well a personalized clotting-factor plan helps people with hemophilia A get rid of inhibitors. It may help doctors refine treatment for patients who develop antibodies that block factor therapy.
This trial tests a study medicine (marstacimab) for children with severe hemophilia A or B, to see if it can help prevent or reduce bleeding episodes. It may be an option for children who do not have certain other health conditions.
Hear when a new Congenital Haemophilia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.